Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

As Hain Celestial gears up to become a “pure play” food and beverage supplier, the company sees opportunities linked to GLP-1 ...

It fell last week after the company released updated guidance, with revenue for its GLP-1 drugs projected ... For Zepbound, which is approved for weight loss, revenue of $1.9 billion is a bit ...

Pfizer revealed in December that it had decided to drop the twice-daily version, after seeing rates of discontinuation with the drug above 50% in clinical testing, despite weight loss ranging from ...

Sales of Danone’s popular yogurt brands are finding a more prominent place on the menu with consumers who are eating less as a result of using Ozempic and other popular weight-loss drugs.

Some background: Wegovy belongs to a new class of weight-loss drugs known as semaglutides ... These drugs are known as GLP-1 agonists. GLP-1 is a naturally occurring hormone that works with your brain ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

This can help individuals feel fuller for longer and can promote weight loss. When measured by traditional weight loss ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...